Ticagrelor FDA Approval Issues Revisited

Publisher： Karger

E-ISSN： 1421-9751|122|3|144-147

ISSN： 0008-6312

Source： Cardiology, Vol.122, Iss.3, 2012-07, pp. : 144-147

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Vireo to to seek FDA approval for nonsmokeable cannabis

By  

ALCOHOLISM AND DRUG ABUSE WEEKLY, Vol. 27, Iss. 47, 2015-12 ,pp. : 4-5

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ticagrelor

By  

PRACTICAL DIABETES (INCORPORATING CARDIABETES), Vol. 33, Iss. 7, 2016-09 ,pp. : 258-259

John Wiley & Sons Inc

Access to resources Recommend Favorite

FDA issues final guidance on abuse‐deterrent opioids

By  

ALCOHOLISM AND DRUG ABUSE WEEKLY, Vol. 27, Iss. 15, 2015-04 ,pp. : 6-6

John Wiley & Sons Inc

Access to resources Recommend Favorite

FDA issues final guidance on abuse‐deterrent opioids

By  

THE BROWN UNIVERSITY CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY UPDATE, Vol. 17, Iss. 5, 2015-05 ,pp. : 8-8

John Wiley & Sons Inc

Access to resources Recommend Favorite

The FDA Outlook of Events Reporting after Ticagrelor or Clopidogrel in the PLATO Trial: Impact of Sponsor Censoring Dates, Drug Discontinuation, and Withdrawal of Consent

By  

Cardiology, Vol. 120, Iss. 3, 2012-01 ,pp. : 169-171

Karger

Access to resources Recommend Favorite